Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">On The Wires<ul><li>Vermillion (<strong>VRML</strong>) announced the acceptance for publication of the original research titled, «Evaluation of a Validated Biomarker Test in Combination With a Symptom Index to Predict Ovarian Malignancy,» by Renata R. Urban, MD, Alan Smith, MS, Kathy Agnew, Vinicius Bonato, PhD, and Barbara A. Goff, MD, in the International Journal of Gynecological Cancer. In a 2016 study performed with 218 patients who presented with pelvic masses, the combination of SI and OVA1 (MIA) showed a sensitivity to detect primary ovarian malignancy of 100%, detecting both early and late stage cancers better than either SI or OVA1 (MIA) alone. Additionally, the negative predictive value of SI and OVA1 combined was also 100%, indicating that all women that tested negative for both tests were certain not to have a primary ovarian malignancy.</li><li>CB&I (<strong>CBI</strong>) announced it has been awarded a substantial contract for the license, engineering design and catalyst supply for five proprietary technologies to be used in an integrated refining and petrochemical project in China. The complex will use BP Paraxylene OPEX advantaged crystallization technology exclusively licensed by CB&I, as well as technology for a vacuum gasoil hydrocracker, diesel hydrocracker, kerosene hydrotreater and delayed coker offered through Chevron Lummus Global (CLG). CLG is a joint venture between Chevron and CB&I.</li><li>Interval International, an operating business of ILG (<strong>ILG</strong>), announced the extension of its agreement with Oyster Bay Beach Resort, a mixed-use property situated on the Dutch Caribbean island of St. Maarten. Under the exclusive, multiyear agreement, Interval will continue to provide membership and exchange services for the luxury retreat's vacation ownership base.</li></ul></td> </tr></table>"